107 related articles for article (PubMed ID: 22643706)
41. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
42. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
[TBL] [Abstract][Full Text] [Related]
43. Malignant transformation of mature T cells after gammaretrovirus mediated transfer of nucleophosmin-anaplastic lymphoma kinase oncogene.
Kumar A
Indian J Pathol Microbiol; 2015; 58(3):301-6. PubMed ID: 26275250
[TBL] [Abstract][Full Text] [Related]
44. An evolutionary stability perspective on oncogenesis control in mature T-cell populations.
Diebner HH; Kirberg J; Roeder I
J Theor Biol; 2016 Jan; 389():88-100. PubMed ID: 26549469
[TBL] [Abstract][Full Text] [Related]
45. TCR-dependent transformation of mature memory phenotype T cells in mice.
Wang X; Werneck MB; Wilson BG; Kim HJ; Kluk MJ; Thom CS; Wischhusen JW; Evans JA; Jesneck JL; Nguyen P; Sansam CG; Cantor H; Roberts CW
J Clin Invest; 2011 Oct; 121(10):3834-45. PubMed ID: 21926465
[TBL] [Abstract][Full Text] [Related]
46. Resistance of mature T cells to oncogene transformation.
Newrzela S; Cornils K; Li Z; Baum C; Brugman MH; Hartmann M; Meyer J; Hartmann S; Hansmann ML; Fehse B; von Laer D
Blood; 2008 Sep; 112(6):2278-86. PubMed ID: 18566328
[TBL] [Abstract][Full Text] [Related]
47. Dual TCR-expressing T lymphocytes in health and disease.
Hinz T; Weidmann E; Kabelitz D
Int Arch Allergy Immunol; 2001 May; 125(1):16-20. PubMed ID: 11385284
[TBL] [Abstract][Full Text] [Related]
48. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.
Kitchen SG; Bennett M; Galić Z; Kim J; Xu Q; Young A; Lieberman A; Joseph A; Goldstein H; Ng H; Yang O; Zack JA
PLoS One; 2009 Dec; 4(12):e8208. PubMed ID: 19997617
[TBL] [Abstract][Full Text] [Related]
49. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate.
Hesterberg RS; Liu M; Elmarsafawi AG; Koomen JM; Welsh EA; Hesterberg SG; Ranatunga S; Yang C; Li W; Lawrence HR; Rodriguez PC; Berglund AE; Cleveland JL
Cancer Immunol Res; 2022 Oct; 10(10):1263-1279. PubMed ID: 35969234
[TBL] [Abstract][Full Text] [Related]
50. Mathematical modeling of oncogenesis control in mature T-cell populations.
Gerdes S; Newrzela S; Glauche I; von Laer D; Hansmann ML; Roeder I
Front Immunol; 2013; 4():380. PubMed ID: 24409176
[TBL] [Abstract][Full Text] [Related]
51. TCR Pathway Mutations in Mature T Cell Lymphomas.
Zhang Y; Cheng K; Choi J
J Immunol; 2023 Nov; 211(10):1450-1458. PubMed ID: 37931208
[TBL] [Abstract][Full Text] [Related]
52. Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology.
Herling M; Rengstl B; Scholtysik R; Hartmann S; Küppers R; Hansmann ML; Diebner HH; Roeder I; Abken H; Newrzela S; Kirberg J
Leuk Lymphoma; 2017 Apr; 58(4):788-796. PubMed ID: 27643643
[TBL] [Abstract][Full Text] [Related]
53. The role of bcl-2 in lymphoid differentiation and neoplastic transformation.
Strasser A; Harris AW; Cory S
Curr Top Microbiol Immunol; 1992; 182():299-302. PubMed ID: 1490367
[No Abstract] [Full Text] [Related]
54. IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.
Amanda S; Tan TK; Ong JZL; Theardy MS; Wong RWJ; Huang XZ; Ali MZ; Li Y; Gong Z; Inagaki H; Foo EY; Pang B; Tan SY; Iida S; Sanda T
Nat Commun; 2022 May; 13(1):2420. PubMed ID: 35504924
[TBL] [Abstract][Full Text] [Related]
55. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications.
Wasik MA; Kim PM; Nejati R
Front Oncol; 2024; 14():1383741. PubMed ID: 38638855
[TBL] [Abstract][Full Text] [Related]
56. Models for mature T-cell lymphomas--a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts.
Warner K; Crispatzu G; Al-Ghaili N; Weit N; Florou V; You MJ; Newrzela S; Herling M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):680-95. PubMed ID: 23972664
[TBL] [Abstract][Full Text] [Related]
57. Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.
Heinrich T; Rengstl B; Muik A; Petkova M; Schmid F; Wistinghausen R; Warner K; Crispatzu G; Hansmann ML; Herling M; von Laer D; Newrzela S
Mol Ther; 2013 Jun; 21(6):1160-8. PubMed ID: 23609016
[TBL] [Abstract][Full Text] [Related]
58. Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Bonini C; Chapuis AG; Hudecek M; Guedan S; Magnani C; Qasim W
Hum Gene Ther; 2023 Sep; 34(17-18):853-869. PubMed ID: 37694593
[TBL] [Abstract][Full Text] [Related]
59. Modifying enzyme replacement therapy - A perspective.
Schaible P
J Cell Mol Med; 2023 Jan; 27(2):165-173. PubMed ID: 36566487
[TBL] [Abstract][Full Text] [Related]
60. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.
Michels A; Ho N; Buchholz CJ
Mol Ther; 2022 Jul; 30(7):2401-2415. PubMed ID: 35598048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
